Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells
We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dio...
Gespeichert in:
Veröffentlicht in: | Journal of controlled release 2001-08, Vol.75 (3), p.381-389 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 389 |
---|---|
container_issue | 3 |
container_start_page | 381 |
container_title | Journal of controlled release |
container_volume | 75 |
creator | Maitani, Yoshie Kawano, Kumi Yamada, Kazuyo Nagai, Tsuneji Takayama, Kozo |
description | We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R. |
doi_str_mv | 10.1016/S0168-3659(01)00411-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17905721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365901004114</els_id><sourcerecordid>17905721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhJ4B8QAgOKZ7Y3jgnhKp-IFXqAThbjj1ZjJJ48SSL8u_Jfqj01stYGj1-Z_QMY29BXICA9efvSzGFXOv6o4BPQiiAQj1jKzCVLFRd6-ds9YCcsVdEv4UQWqrqJTsDUKaWpVqx-apto484-Jmnlndxmyj1SJym3DqPRZ9CbCMG_jeOvziluUE3FAFz3C1NGjHP3aabfKIYkDvibgnZYeajyxsc47Dh3uUcl04c-C1ub0rusevoNXvRuo7wzek9Zz-vr35c3hZ39zffLr_eFV6VMBZONyGUBkxZYS1MA0YJB6C18BJQK1GZFsJaoChRa6P8Go3UTdlUSqoglTxnH46525z-TEij7SPtN3ADpoksVLXQVQkLqI-gz4koY2u3OfYuzxaE3Tu3B-d2L9QKsAfndj_g3WnA1PQY_v86SV6A9yfAkXddm93gIz1KN9LU9YJ9OWK42NgtwiwdDoMhZvSjDSk-sck_u9-eOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17905721</pqid></control><display><type>article</type><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</creator><creatorcontrib>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</creatorcontrib><description>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/S0168-3659(01)00411-4</identifier><identifier>PMID: 11489324</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>alpha-Fetoproteins - pharmacology ; Asialoglycoprotein Receptor ; Asialoglycoproteins - pharmacology ; Biological and medical sciences ; Cholestenes - administration & dosage ; Doxorubicin - administration & dosage ; Drug Carriers ; Endocytosis ; Fetuins ; General pharmacology ; Glycine max ; HepG2 cells ; Humans ; Liposome ; Liposomes ; Liver - metabolism ; Liver targeting ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Receptors, Cell Surface - physiology ; Serum Albumin, Bovine - pharmacokinetics ; Soybean-derived sterylglucoside ; sterylglucoside ; Tumor Cells, Cultured</subject><ispartof>Journal of controlled release, 2001-08, Vol.75 (3), p.381-389</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</citedby><cites>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365901004114$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1083899$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11489324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maitani, Yoshie</creatorcontrib><creatorcontrib>Kawano, Kumi</creatorcontrib><creatorcontrib>Yamada, Kazuyo</creatorcontrib><creatorcontrib>Nagai, Tsuneji</creatorcontrib><creatorcontrib>Takayama, Kozo</creatorcontrib><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</description><subject>alpha-Fetoproteins - pharmacology</subject><subject>Asialoglycoprotein Receptor</subject><subject>Asialoglycoproteins - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cholestenes - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Carriers</subject><subject>Endocytosis</subject><subject>Fetuins</subject><subject>General pharmacology</subject><subject>Glycine max</subject><subject>HepG2 cells</subject><subject>Humans</subject><subject>Liposome</subject><subject>Liposomes</subject><subject>Liver - metabolism</subject><subject>Liver targeting</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Serum Albumin, Bovine - pharmacokinetics</subject><subject>Soybean-derived sterylglucoside</subject><subject>sterylglucoside</subject><subject>Tumor Cells, Cultured</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhJ4B8QAgOKZ7Y3jgnhKp-IFXqAThbjj1ZjJJ48SSL8u_Jfqj01stYGj1-Z_QMY29BXICA9efvSzGFXOv6o4BPQiiAQj1jKzCVLFRd6-ds9YCcsVdEv4UQWqrqJTsDUKaWpVqx-apto484-Jmnlndxmyj1SJym3DqPRZ9CbCMG_jeOvziluUE3FAFz3C1NGjHP3aabfKIYkDvibgnZYeajyxsc47Dh3uUcl04c-C1ub0rusevoNXvRuo7wzek9Zz-vr35c3hZ39zffLr_eFV6VMBZONyGUBkxZYS1MA0YJB6C18BJQK1GZFsJaoChRa6P8Go3UTdlUSqoglTxnH46525z-TEij7SPtN3ADpoksVLXQVQkLqI-gz4koY2u3OfYuzxaE3Tu3B-d2L9QKsAfndj_g3WnA1PQY_v86SV6A9yfAkXddm93gIz1KN9LU9YJ9OWK42NgtwiwdDoMhZvSjDSk-sck_u9-eOQ</recordid><startdate>20010810</startdate><enddate>20010810</enddate><creator>Maitani, Yoshie</creator><creator>Kawano, Kumi</creator><creator>Yamada, Kazuyo</creator><creator>Nagai, Tsuneji</creator><creator>Takayama, Kozo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20010810</creationdate><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><author>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>alpha-Fetoproteins - pharmacology</topic><topic>Asialoglycoprotein Receptor</topic><topic>Asialoglycoproteins - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cholestenes - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Carriers</topic><topic>Endocytosis</topic><topic>Fetuins</topic><topic>General pharmacology</topic><topic>Glycine max</topic><topic>HepG2 cells</topic><topic>Humans</topic><topic>Liposome</topic><topic>Liposomes</topic><topic>Liver - metabolism</topic><topic>Liver targeting</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Serum Albumin, Bovine - pharmacokinetics</topic><topic>Soybean-derived sterylglucoside</topic><topic>sterylglucoside</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maitani, Yoshie</creatorcontrib><creatorcontrib>Kawano, Kumi</creatorcontrib><creatorcontrib>Yamada, Kazuyo</creatorcontrib><creatorcontrib>Nagai, Tsuneji</creatorcontrib><creatorcontrib>Takayama, Kozo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maitani, Yoshie</au><au>Kawano, Kumi</au><au>Yamada, Kazuyo</au><au>Nagai, Tsuneji</au><au>Takayama, Kozo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2001-08-10</date><risdate>2001</risdate><volume>75</volume><issue>3</issue><spage>381</spage><epage>389</epage><pages>381-389</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11489324</pmid><doi>10.1016/S0168-3659(01)00411-4</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2001-08, Vol.75 (3), p.381-389 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_17905721 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | alpha-Fetoproteins - pharmacology Asialoglycoprotein Receptor Asialoglycoproteins - pharmacology Biological and medical sciences Cholestenes - administration & dosage Doxorubicin - administration & dosage Drug Carriers Endocytosis Fetuins General pharmacology Glycine max HepG2 cells Humans Liposome Liposomes Liver - metabolism Liver targeting Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Receptors, Cell Surface - physiology Serum Albumin, Bovine - pharmacokinetics Soybean-derived sterylglucoside sterylglucoside Tumor Cells, Cultured |
title | Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficiency%20of%20liposomes%20surface-modified%20with%20soybean-derived%20sterylglucoside%20as%20a%20liver%20targeting%20carrier%20in%20HepG2%20cells&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Maitani,%20Yoshie&rft.date=2001-08-10&rft.volume=75&rft.issue=3&rft.spage=381&rft.epage=389&rft.pages=381-389&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/S0168-3659(01)00411-4&rft_dat=%3Cproquest_cross%3E17905721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17905721&rft_id=info:pmid/11489324&rft_els_id=S0168365901004114&rfr_iscdi=true |